The Society for Neuroscience Annual Meeting is a premier event for neuroscientists, clinicians, and students to discuss and exchange scientific research. This event is essential for those aiming to stay current in neuroscience advancements and network with leading experts.
The Society for Neuroscience Annual Meeting is a crucial event for anyone involved in the field of neuroscience, offering comprehensive exposure to the latest research, developments, and technologies. Attendees can expect presentations from esteemed neuroscientists, hands-on workshops, and engaging panel discussions that cover a wide range of topics from foundational research to applied neurotechnology. Networking with peers and experts provides additional invaluable opportunities to enhance understanding and foster collaborations.
What you will learn
Latest breakthroughs in neuroscience research.
Networking opportunities with industry experts.
Insights into new neurotechnology and methodologies.
Understanding of neuroscience's clinical applications.
Future trends and directions in neuroscience.
Want to exhibit at this event?
MarketScale can act as a third-party concierge, helping you request exhibitor packages, pricing, and booth availability. No cold calls, no commitment.
Key Highlights
• Presentations by leading neuroscientists.
• Workshops on cutting-edge research methodologies.
• Panel discussions on neuroscience innovations.
• Opportunities to publish and present research.
Frequently asked questions
Topics & tracks
MarketScale platform
Exhibiting at this event?
Capture customer testimonials onsite, with your iPhone.
MarketScale turns every booth conversation into a produced video clip, written article, and social posts. No crew. No editing. Done before you land home.
Learn how →sciences articles
Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade
More than $300 billion in branded pharmaceutical revenue faces patent expiration by 2030. Big Pharma cannot replace it through internal R&D alone. The result is the most aggressive acquisition cycle since before the pandemic, and it is reshaping how the entire life sciences supply chain does business.
Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic
Quotient Sciences initiates what it calls the first Phase I trial of an AI-designed oral drug formulation, approved by the UK's MHRA.
Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic
Quotient Sciences has initiated a Phase I study of an AI-designed oral formulation, cleared by the MHRA—marking a concrete shift from AI experimentation to clin
MarketScale
MarketScale helps B2B teams cover events like this and turn them into content their market reads. Want to talk through what that looks like?